Cingulate Island Sign in Single Photon Emission Computed Tomography: Clinical Biomarker Correlations in Lewy Body Disease and Alzheimer’s Disease

Article type: Short Communication

Authors: Futamura, Akinori^{a; *} | Hieda, Sotaro^a | Mori, Yukiko^a | Sugimoto, Azusa^a | Kasai, Hideyo^a | Kuroda, Takeshi^a | Yano, Satoshi^a | Kasuga, Kensaku^b | Murakami, Hidetomo^{a; c} | Ikeuchi, Takeshi^b | Ono, Kenjiro^a

Affiliations: [a] Division of Neurology, Department of Medicine, Showa University School of Medicine, Shinagawa-ku, Tokyo, Japan | [b] Department of Molecular Genetics, Brain Research Institute, Niigata University, Chuo-ku, Niigata, Japan | [c] Department of Neurology, School of Medicine, The Jikei University, Minato-ku, Tokyo, Japan

Correspondence: [*] Correspondence to: Kenjiro Ono, Division of Neurology, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan. Tel.: +81 3 3784 8710; Fax: +81 3784 8710; E-mail: onoken@med.showa-u.ac.jp.

Abstract: We compared ‘CIScore’ determined by quantitative single photon emission computed tomography studies of the cingulate island sign to cerebrospinal fluid (CSF) biomarkers in Lewy body disease (LBD) and Alzheimer’s disease (AD) to assess its usefulness and pathological background. Among the 16 each age-matched LBD and AD patients, the CIScore differed significantly but was not correlated with CSF biomarkers. In LBD, hippocampal atrophy significantly correlated with Clinical Dementia Rating and CSF p-tau and t-tau levels. Our results showed CIS was not related to CSF biomarkers in LBD and high CSF tau levels were related to clinical disease severity and hippocampal atrophy.

Keywords: Alzheimer’s disease, amyloid β-protein 42, cingulate island sign, Lewy body disease, medial temporal atrophy, phosphorylated tau protein

DOI: 10.3233/JAD-201145

Journal: Journal of Alzheimer's Disease, vol. 79, no. 3, pp. 1003-1008, 2021